|
1
|
Esteller M: Cancer epigenetics for the
21st century: what’s next? Genes Cancer. 2:604–606. 2011.
|
|
2
|
Daniel FI, Cherubini K, Yurgel LS, de
Figueiredo MA and Salum FG: The role of epigenetic transcription
repression and DNA methyltransferases in cancer. Cancer.
117:677–687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bender CM, Pao MM and Jones PA: Inhibition
of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth
of human tumor cell lines. Cancer Res. 58:95–101. 1998.
|
|
4
|
Fang JY, Cheng ZH, Chen YX, Lu R, Yang L,
Zhu HY and Lu LG: Expression of Dnmt1, demethylase, MeCP2 and
methylation of tumor-related genes in human gastric cancer. World J
Gastroenterol. 10:3394–3398. 2004.PubMed/NCBI
|
|
5
|
Vertino PM, Yen RW, Gao J and Baylin SB:
De novo methylation of CpG island sequences in human fibroblasts
overexpression DNA (cytosine-5-)-methyltransferase. Mol Cell Biol.
16:4555–4565. 1996.PubMed/NCBI
|
|
6
|
Jung Y, Park J and Kim TY, Park JH, Jong
HS, Im SA, Robertson KD, Bang YJ and Kim TY: Potential advantages
of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer
therapy. J Mol Med (Berl). 85:1137–1148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Foo WC, Liegl-Atzwanger B and Lazar AJ:
Pathology of gastrointestinal stromal tumors. Clin Med Insights
Pathol. 5:23–33. 2012.
|
|
8
|
Fletcher CD, Berman JJ, Corless C,
Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti
H, Rubin BP, Shmookler B, Sobin LH and Weiss SW: Diagnosis of
gastrointestinal stromal tumors: a consensus approach. Int J Surg
Pathol. 10:81–89. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y and Kitamura
Y: Gain-of-function mutations of c-kit in human gastrointestinal
stromal tumors. Science. 279:577–580. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heinrich MC, Corless CL, Demetri GD,
Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den
Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S,
Fletcher CD, Silberman S, Dimitrijevic S and Fletcher JA: Kinase
mutations and imatinib response in patients with metastatic
gastrointestinal stromal tumor. J Clin Oncol. 21:4342–4349. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miettinen M, Sobin LH and Lasota J:
Gastrointestinal stromal tumors of the stomach: a
clinicopathologic, immunohistochemical, and molecular genetic study
of 1765 cases with long-term follow-up. Am J Surg Pathol. 29:52–68.
2005. View Article : Google Scholar
|
|
12
|
Novelli M, Rossi S, Rodriguez-Justo M,
Taniere P, Seddon B, Toffolatti L, Sartor C, Hogendoorn PC, Sciot
R, Van Glabbeke M, Verweij J, Blay JY, Hohenberger P, Flanagan A
and Dei Tos AP: DOG1 and CD117 are the antibodies of choice in the
diagnosis of gastrointestinal stromal tumours. Histopathology.
57:259–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Janeway KA, Liegl B, Harlow A, Le C,
Perez-Atayde A, Kozakewich H, Corless CL, Heinrich MC and Fletcher
JA: Pediatric KIT wild-type and platelet-derived growth factor
receptor alpha-wild-type gastrointestinal stromal tumors share KIT
activation but not mechanisms of genetic progression with adult
gastrointestinal stromal tumors. Cancer Res. 67:9084–9088. 2007.
View Article : Google Scholar
|
|
14
|
Demetri GD, von Mehren M, Antonescu CR,
DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF,
Schuetze S, Sundar HM, Trent JC and Wayne JD: NCCN Task Force
report: update on the management of patients with gastrointestinal
stromal tumors. J Natl Compr Canc Netw. 8(Suppl 2): S1–S44.
2010.PubMed/NCBI
|
|
15
|
Schaefer M, Hagemann S, Hanna K and Lyko
F: Azacytidine inhibits RNA methylation at DNMT2 target sites in
human cancer cell lines. Cancer Res. 69:8127–8132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ooi SK, Qiu C, Bernstein E, Li K, Jia D,
Yang Z, Erdjument-Bromage H, Tempst P, Lin SP, Allis CD, Cheng X
and Bestor TH: DNMT3L connects unmethylated lysine 4 of histone H3
to de novo methylation of DNA. Nature. 448:714–717. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bourc’his D, Xu GL, Lin CS, Bollman B and
Bestor TH: Dnmt3L and the establishment of maternal genomic
imprints. Science. 294:2536–2539. 2001.PubMed/NCBI
|
|
18
|
Jia D, Jurkowska RZ, Zhang X, Jeltsch A
and Cheng X: Structure of Dnmt3a bound to Dnmt3L suggests a model
for de novo DNA methylation. Nature. 449:248–251. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu D, Hunter SB, Vertino PM and Van Meir
EG: Overexpression of MBD2 in glioblastoma maintains epigenetic
silencing and inhibits the antiangiogenic function of the tumor
suppressor gene BAI1. Cancer Res. 71:5859–5870. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fuso A, Nicolia V, Cavallaro RA and Scarpa
S: DNA methylase and demethylase activities are modulated by
one-carbon metabolism in Alzheimer’s disease models. J Nutr
Biochem. 22:242–251. 2011.PubMed/NCBI
|
|
21
|
Rountree MR, Bachman KE, Herman JG and
Baylin SB: DNA methylation, chromatin inheritance, and cancer.
Oncogene. 20:3156–3165. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ding WJ, Fang JY, Chen XY and Peng YS: The
expression and clinical significance of DNA methyltransferase
proteins in human gastric cancer. Dig Dis Sci. 53:2083–2089. 2008.
View Article : Google Scholar : PubMed/NCBI
|
